47N Stock Overview
A late-stage biopharmaceutical company, engages in the development and commercialization of critical care products.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Citius Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.49 |
52 Week High | US$0.93 |
52 Week Low | US$0.43 |
Beta | 1.68 |
11 Month Change | -39.55% |
3 Month Change | -19.71% |
1 Year Change | -40.39% |
33 Year Change | -71.83% |
5 Year Change | n/a |
Change since IPO | -73.64% |
Recent News & Updates
Recent updates
Shareholder Returns
47N | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -0.2% | 1.7% | 1.5% |
1Y | -40.4% | -15.4% | 6.2% |
Return vs Industry: 47N underperformed the German Pharmaceuticals industry which returned -15.4% over the past year.
Return vs Market: 47N underperformed the German Market which returned 6.2% over the past year.
Price Volatility
47N volatility | |
---|---|
47N Average Weekly Movement | 15.9% |
Pharmaceuticals Industry Average Movement | 5.3% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 11.5% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 47N's share price has been volatile over the past 3 months.
Volatility Over Time: 47N's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 22 | Leonard Mazur | citiuspharma.com |
Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company, engages in the development and commercialization of critical care products. The company's diversified pipeline includes two late-stage product candidates, Mino-Lok and LYMPHIR. The company has enrollment in a Phase 3 pivotal trial of Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections.
Citius Pharmaceuticals, Inc. Fundamentals Summary
47N fundamental statistics | |
---|---|
Market cap | €93.21m |
Earnings (TTM) | -€35.98m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs 47N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
47N income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$39.77m |
Earnings | -US$39.77m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.22 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 47N perform over the long term?
See historical performance and comparison